Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
The CCTG Phase III Team Award for Intergroup-Led Trials was presented to the CO29 Team BCCA from Vancouver Cancer Centre and the Annual Spring Meeting. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance.
Dr. Courtney Coschi was recognized with the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting. The award is presented to a new investigator who has worked at the CCTG Central Office, IND projects, or has contributed significantly to the conduct of an IND trial at a member centre.
Congrats to the MA39 clinical trials team at Tom Baker Cancer Centre in Calgary for receiving the ,Phase III Team Award for CCTG-Led Trials at a ceremony recently held at the Annual Spring Meeting in Toronto. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance
Congratulations to the PR19 Team from the Odette Cancer Centre at Sunnybrook for being recognized with the Phase III Team Award for CCTG-Led Trials.
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr. Jolie Ringash, a radiation oncologist at the University of Toronto. The award is presented yearly at the Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG former Directors joint statement regarding US requirements for identity proofing and multi-factor authentication
Congratulations to Dr. Ali Hosni Abdalaty from Princess Margaret Cancer Centre (UHN) for his Ralph Meyer Phase III Program Young Investigator Award received at the CCTG Spring Meeting.